Felzartamab is named as a drug or biological intervention in 6 clinical trials in our USA, India, China and UK trial registers, 4 of which are recruiting. The lead sponsor is Biogen. Registered phases: Phase 3 and Phase 2. Conditions studied include Antibody-mediated Rejection; Microvascular Inflammation; Immunoglobulin A Nephropathy (IgAN).
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Antibody-mediated Rejection | 2 |
| Microvascular Inflammation | 2 |
| Immunoglobulin A Nephropathy (IgAN) | 1 |
| Primary Membranous Nephropathy | 1 |
| Graves' Disease | 1 |
| Lead sponsor | Trials |
|---|---|
| Biogen | 6 |
| Register | Felzartamab trials |
|---|---|
| Clinical trials in USA | 6 |
| Clinical trials in India | 2 |
| Clinical trials in China | 2 |
| Clinical trials in UK | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Felzartamab works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Felzartamab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.